Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Qiuxiao Guo"'
Autor:
Ningning Guo, Di Zheng, Jiaxin Sun, Jian Lv, Shun Wang, Yu Fang, Zhenyi Zhao, Sai Zeng, Qiuxiao Guo, Jingjing Tong, Zhihua Wang
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Pathological growth of cardiomyocytes during hypertrophy is characterized by excess protein synthesis; however, the regulatory mechanism remains largely unknown. Using a neonatal rat ventricular myocytes (NRVMs) model, here we find that the expressio
Externí odkaz:
https://doaj.org/article/f0c867487e304a2eabbb77df40210b6c
Publikováno v:
Current Drug Targets. 24:371-378
aims: To elucidate the roles of PRC2 and HDACs in cardiomyocyte hypertrophy. background: Postnatal cardiomyocytes respond to stress signals by hypertrophic growth and fetal gene reprogramming, which involves epigenetic remodeling mediated by histone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c30f15ea5619190ea540bc64c590cb8
https://doi.org/10.2174/1389450124666230124094936
https://doi.org/10.2174/1389450124666230124094936
Autor:
Yishan Huang, Cairong Zhu, Xiangfeng Zeng, Tian-Xiang Wang, Heng Wang, Qiuxiao Guo, Liankuai Chen, Xiaomian Lin, Hongjiao Liu, Rong-zhen Li, Xiaoping Wu
Publikováno v:
Anti-Cancer Drugs. 30:973-982
Fibroblast growth factor-2 (FGF2) is a protein ligand, which exerts essential roles in development, angiogenesis, and tumor progression via activation of the downstream signaling cascades. Accumulating evidence has demonstrated that FGF2 is involved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f50ef98147bbf69d7d7d0979960d06
https://doi.org/10.1097/cad.0000000000000830
https://doi.org/10.1097/cad.0000000000000830
Autor:
Hongjiao Liu, Xiangpeng Tan, Xiaoping Wu, Yishan Huang, Jialong Cai, Xiangfeng Zeng, Qiuxiao Guo, Xiaomian Lin, Cairong Zhu, Liankuai Chen
Publikováno v:
European journal of pharmacology. 880
Prostate cancer (PCa) is the most common malignancy among men. Tumor metastasis and chemoresistance contribute to the major cause of the mortality. In this study, we compared the protein profiles of two prostate cancer cell lines with different metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c619c71e640d1049b5f777e46fa012fc
https://pubmed.ncbi.nlm.nih.gov/32320704
https://pubmed.ncbi.nlm.nih.gov/32320704
Autor:
Xiangpeng Tan, Qiuxiao Guo, Xiaomian Lin, Xiaoping Wu, Rong-zhen Li, Liankuai Chen, Yishan Huang, Jizhong Wang, Heng Wang, Xiangfeng Zeng
Publikováno v:
Pharmacological research. 152
Aberrant over-expressions of FGF9 in gastric cancer (GC) and its high-affinity receptor FGFR3c in bladder cancer (BC) provide possibilities for the treatment of GC and BC via targeting FGF9. In this study, we isolated a novel FGF9-binding peptide (P4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9cd6e8b99c03b04e85d7907c2997a9a
https://pubmed.ncbi.nlm.nih.gov/31805343
https://pubmed.ncbi.nlm.nih.gov/31805343
Autor:
Yi-shan Huang, Tian-xiang Wang, Xiao-mian Lin, Heng Wang, Rong-zhen Li, Xiangfeng Zeng, Cairong Zhu, Lian-kuai Chen, Qiuxiao Guo, Hongjiao Liu, Xiao-ping Wu
Publikováno v:
Anti-Cancer Drugs; Nov2019, Vol. 30 Issue 10, p973-982, 10p